Rifampicin Breadcrumb Home Glossary Rifampicin Short description Rifampicin is an antibiotic especially used to treat mycobacterial infections. Detailed description Rifampicin inhibits the RNA polymerase – a bacterial enzyme needed for protein production. More about “Rifampicin” Aug 2024 Open Forum Infect Dis Reflex Xpert MTB/XDR Testing of Residual Rifampicin-Resistant Specimens: A Clinical Laboratory-Based Diagnostic Accuracy and Feasibility Study in South Africa Autoren Centner CM et al. May 2024 Respiration Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland Autoren Otto-Knapp R et al. Jun 2024 Clin Microbiol Infect Re: 'Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe' by Lange et al Autoren Friesen I et al. Jun 2024 Clin Microbiol Infect Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response Autoren Lange C et al. Mar 2024 Clin Microbiol Infect Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe Autoren Günther G et al. Nov 2023 Pneumologie [Treatment of MDR, pre-XDR, XDR and rifampicin resistant TB or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment to the Sk2-Guideline: TB in adulthood of the DZK on behalf of the DGP] Autoren Otto-Knapp R et al. Oct 2023 Nat Commun Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis Autoren Menzies NA et al. Feb 2024 Nat Med A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial Autoren Diacon AH et al. © FZB/Weller Nov 10 2023 When (new) drugs don’t work: Mozambique faces alarming multidrug-resistant tuberculosis epidemic With one of the highest tuberculosis (TB) incidences (368 cases/100,000 population) in the African region, Mozambique is particularly affected by the TB epidemic. Drug-resistant TB is also a major Jul 2023 Liver Int Rifaximin may induce rifampicin resistance in coagulase-negative staphylococci Autoren Schulte LM et al. Pagination < Zurück Current page 1 Seite 2 Seite 3 Seite 4 Seite 1 Seite 2 Seite 3 Seite 4 Next page ››
Aug 2024 Open Forum Infect Dis Reflex Xpert MTB/XDR Testing of Residual Rifampicin-Resistant Specimens: A Clinical Laboratory-Based Diagnostic Accuracy and Feasibility Study in South Africa Autoren Centner CM et al.
May 2024 Respiration Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland Autoren Otto-Knapp R et al.
Jun 2024 Clin Microbiol Infect Re: 'Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe' by Lange et al Autoren Friesen I et al.
Jun 2024 Clin Microbiol Infect Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response Autoren Lange C et al.
Mar 2024 Clin Microbiol Infect Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe Autoren Günther G et al.
Nov 2023 Pneumologie [Treatment of MDR, pre-XDR, XDR and rifampicin resistant TB or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment to the Sk2-Guideline: TB in adulthood of the DZK on behalf of the DGP] Autoren Otto-Knapp R et al.
Oct 2023 Nat Commun Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis Autoren Menzies NA et al.
Feb 2024 Nat Med A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial Autoren Diacon AH et al.
Jul 2023 Liver Int Rifaximin may induce rifampicin resistance in coagulase-negative staphylococci Autoren Schulte LM et al.
